Dye composition comprising an oxidation base of the diaminopyrazole type, a cationic oxidation base and a coupler

ABSTRACT

Dye compositions comprising, in a medium suitable for dyeing:  
     at least one first oxidation base chosen from 4,5-diaminopyrazole derivatives of formula (I) and addition salts thereof,  
     at least one second cationic oxidation base chosen from monobenzenic, dibenzenic and heterocyclic oxidation bases, and the addition salts thereof, comprising at least one cationic group Z chosen from aliphatic chains optionally bearing at least one ring chosen from saturated and unsaturated rings; wherein said at least one cationic group Z is linked directly to at least one benzenic ring or to at least one heterocycle of said at least one second cationic oxidation base or linked to at least one amine functional group borne by said at least one benzenic ring or said at least one heterocycle; and  
     at least one coupler;  
     as well as the use of this composition for dyeing keratin fibres and the dying process using this composition.

[0001] This application claims benefit of U.S. Provisional ApplicationNo. 60/372,452, filed Apr. 16, 2002.

[0002] The disclosure relates to a dye composition comprising, in amedium suitable for dyeing, at least one first oxidation base of thediaminopyrazole type, at least one second cationic oxidation base chosenfrom monobenzenic, dibenzenic and heterocyclic oxidation bases and atleast one coupler.

[0003] It is a well-known practice to dye keratin fibres, such as humanhair, with dye compositions comprising oxidation dye precursors,generally known as oxidation bases, such as ortho- orpara-phenylenediamines, ortho- or para-aminophenols and heterocycliccompounds. These oxidation bases are colourless or weakly colouredcompounds, that, when combined with oxidizing products, may give rise tocoloured compounds by a process of oxidative condensation.

[0004] It is also well-known that the shades obtained with theseoxidation bases may be varied by combining them with couplers orcoloration modifiers. The couplers or coloration modifiers may bechosen, for example, from aromatic meta-diamines, metaminophenols,meta-diphenols and certain heterocyclic compounds, such as indolecompounds.

[0005] The variety of molecules used as oxidation bases and couplersmake it possible, for example, to obtain a wide range of colours.

[0006] The “permanent” coloration obtained by means of these oxidationdyes should moreover satisfy a number of properties. For example, itshould have no toxicological drawbacks. It should, further for example,allow shades to be obtained in the desired intensity. And it should,even further for example, show good resistance to external agents suchas light, bad weather, washing, permanent waving, perspiration andrubbing.

[0007] The oxidation dyes should be able to make it possible, forexample, to cover white hair. And the oxidation dyes should also be asunselective as possible, i.e. they should produce the smallest possiblecolour differences along the same length of keratin fibre, which isgenerally differently sensitized (i.e. damaged) between its end and itsroot.

[0008] Dye compositions comprising diaminopyrazole derivatives asoxidation bases are already known. For example, Patent Application No.DE 3 843 892 discloses dye compositions for dyeing keratin fibres,comprising 4,5-diaminopyrazole derivatives that may be substituted inposition 2 with alkyl or hydroxyalkyl radicals. Patent Application No.EP 692 245 discloses dye compositions comprising 4,5-diaminopyrazolederivatives combined with particular meta-phenylenediamines. PatentApplication No. DE 196 43 059 discloses dye compositions combining4,5-diaminopyrazole derivatives with metaminophenol andmeta-phenylenediamine couplers. Patent Application No. DE 196 46 609discloses dye compositions combining 4,5-diaminopyrazole derivativeswith benzoxazine couplers.

[0009] Dye compositions comprising para-phenylenediamines containing analiphatic or cyclic cationic group are furthermore known in PatentApplication Nos. WO 99/03819 and WO 99/03836.

[0010] However, the shades obtained with dye compositions comprisingthis type of oxidation base may not be, for example, sufficientlystrong, chromatic and/or fast.

[0011] Accordingly, embodiments of this disclosure provide, for example,novel dye compositions for dyeing keratin fibres, comprisingdiaminopyrazole derivatives, which can overcome at least one of thedrawbacks of the prior art. For example, one embodiment of thisdisclosure provides dye compositions comprising diaminopyrazolederivatives that may be relatively unselective and particularly fast,while at the same time being capable of generating intense colorationsin varied shades.

[0012] Disclosed herein is a dye composition comprising, in a mediumsuitable for dyeing:

[0013] at least one first oxidation base chosen from 4,5-diaminopyrazolederivatives of formula (I) and the addition salts thereof,

[0014] wherein:

[0015] R¹-is chosen from C₁-C₆ alkyl radicals substituted with at leastone radical chosen from OR² radicals wherein R² is chosen from C₁-C₆alkyl radicals;

[0016] at least one second cationic oxidation base chosen frommonobenzenic, dibenzenic, and heterocyclic oxidation bases, and theaddition salts thereof, wherein said at least one second cationicoxidation base comprises at least one cationic group Z chosen fromaliphatic chains optionally bearing at least one ring chosen fromsaturated and unsaturated rings; wherein said at least one cationicgroup Z is linked directly to at least one benzenic ring or to at leastone heterocycle of the said at least one second cationic oxidation baseor linked to at least one amine functional group borne by said at leastone benzenic ring or said at least one heterocycle; and

[0017] at least one coupler.

[0018] The composition disclosed herein may, for example, make itpossible to obtain at least one of chromatic, very strong, relativelyunselective, and fast coloration of keratin fibres.

[0019] Further disclosed herein is the use of the composition for dyeingkeratin fibres, for example, human keratin fibres such as the hair.

[0020] Even further disclosed herein are a dyeing device and a dyeingprocess using the composition.

[0021] As defined herein, the 4,5-diaminopyrazole derivatives of formula(I) further include any corresponding tautomer thereof, where atautomeric equilibrium exists.

[0022] In one embodiment, the at least one first oxidation base ischosen from 4,5 diaminopyrazole derivatives of formula (I) and theaddition salts thereof, wherein R¹ is chosen from C₁-C₄ alkyl radicals,for example, C₂-C₄ alkyl radicals substituted with at least one radicalchosen from OR² radicals, wherein R² is chosen from C₁-C₄ alkylradicals, for example, C₁-C₂ alkyl radicals. Further, for example, theat least one first oxidation base is chosen from4,5-diamino-1-(2′-methoxyethyl)pyrazole and the addition salts thereof.

[0023] As used herein, the term “alkyl” means linear or branchedradicals, for example, methyl, ethyl, n-propyl, isopropyl, butyl, etc.An alkoxy radical is a radical alkyl-O wherein the alkyl radical has thedefinition given above. The term “halogen” means an entity chosen from,for example, Cl, Br, I and F.

[0024] In one embodiment, the at least one second cationic oxidationbase is chosen from monobenzenic, dibenzenic, and heterocyclic oxidationbases, and the addition salts thereof, wherein said at least one secondcationic oxidation base comprises at least one cationic group Z chosenfrom aliphatic chains optionally bearing at least one ring chosen fromsaturated and unsaturated rings; wherein said at least one cationicgroup Z is linked directly to at least one benzenic ring or to at leastone heterocycle of said at least one second cationic oxidation base, orlinked to at least one amine functional group borne by said at least onebenzenic ring or said heterocycle, and

[0025] the at least one cationic group Z is chosen, for example, fromunsaturated cationic groups of formulae (II) and (III) below, andsaturated cationic groups of formula (IV) below:

[0026] wherein:

[0027] D is a linking arm chosen from linear and branched alkylenechains, comprising, for example, from 1 to 14 carbon atoms, which may beinterrupted with at least one hetero atom chosen, for example, fromoxygen, sulphur and nitrogen atoms, and which may be substituted with atleast one radical chosen from hydroxyl and C₁-C₆ alkoxy radicals, andwhich may bear at least one ketone functional group;

[0028] the ring members E, G, J, L and M, which may be identical ordifferent, are each chosen from carbon, oxygen, sulphur and nitrogenatoms;

[0029] n is an integer ranging from 0 to 4;

[0030] m is an integer ranging from 0 to 5;

[0031] R and R₇ to R₁₁, which may be identical or different, are eachchosen from halogen atoms, a hydroxyl radical, amino groups, cyanogroups, amido groups, SO₃X groups, aryl groups, and Z₁, OZ₁, NHZ₁ andNZ₁Z₂ radicals; two of the radicals chosen from R₈, R₉ and R₁₀ may forma 5- or 6-membered saturated heterocycle, which may be interrupted withat least one additional hetero atom chosen, for example, from oxygen,sulphur and nitrogen atoms and which may comprise at least onesubstituent chosen from hydroxyl, amino, halogen, cyano, amido and CO₂Xgroups, C₁-C₆ alkyl radicals, C₁-C₆ alkoxy radicals, C₁-C₆monoalkylamino radicals and C₁-C₆ dialkylamino radicals;

[0032] Z₁ and Z₂, which may be identical or different, are each chosenfrom linear and branched C₁-C₁₄ hydrocarbon-based chains, which may beinterrupted with at least one hetero atom chosen, for example, fromoxygen, sulphur and nitrogen atoms and which may comprise at least onesubstituent chosen from hydroxyl, amino, amido, halogen, cyano and CO₂Xgroups, C₁-C₆ alkyl radicals, C₁-C₆ alkoxy radicals, C₁-C₆monoalkylamino radicals and C₁-C₆ dialkylamino radicals;

[0033] X is chosen from hydrogen, alkali metal and alkaline-earth metalresidues, ammonium ions, C₁-C₆ alkyl radicals and residues derived froman organic amine;

[0034] Y⁻ is an anion chosen from mbnovalent and divalent anions derivedfrom at least one acid chosen from mineral and organic acids and is, forexample, chosen from halogens such as chlorine, bromine, fluorine andiodine, a hydrogen sulphate, and (C₁-C₆)alkyl sulphates such as methylsulphate and ethyl sulphate;

[0035] x and y are integers equal to 0 or 1; with the followingconditions:

[0036] in the unsaturated cationic groups of formula (II):

[0037] when x=0, the linking arm D is attached to the nitrogen atom ofthe unsaturated ring,

[0038] when x=1, the linking arm D is attached to one of the ringmembers E, G, J or L,

[0039] y can take the value 1 only:

[0040] 1) when the ring members E, G, J and L simultaneously are each acarbon atom, and when the radical R₇ is borne by the nitrogen atom ofthe unsaturated ring; or

[0041] 2) when at least one of the ring members E, G, J and L is anitrogen atom to which the radical R₇ is attached;

[0042] in the unsaturated cationic groups of formula (III):

[0043] when x=0, the linking arm D is attached to the nitrogen atom ofthe unsaturated ring,

[0044] when x=1, the linking arm D is attached to one of the ringmembers E, G, J, L or M,

[0045] y can take the value 1 only when at least one of the ring membersE, G, J, L and M is a divalent atom, and when the radical R₇ is borne bythe nitrogen atom of the unsaturated ring;

[0046] in the cationic groups of formula (IV):

[0047] when x=0, then the linking arm is attached to the nitrogen atombearing the radicals R₈ to R₁₀,

[0048] when x=1, then two of the radicals chosen from R₈, R₉ and R₁₀form, together with the nitrogen atom to which they are attached, a 5-or 6-membered saturated ring as defined above, and the linking arm D isborne by a carbon atom of said saturated ring.

[0049] The unsaturated rings of the groups Z of formula (II) above maybe chosen, for example, from pyrrole, imidazole, pyrazole, oxazole,thiazole and triazole rings.

[0050] The unsaturated rings of the groups Z of formula (III) above, maybe chosen, for example, from pyridine, pyrimidine, pyrazine, oxazine andtriazine rings.

[0051] The saturated rings of the groups Z of formula (IV) above may bechosen, for example, from pyrrolidine, piperidine, piperazine andmorpholine rings.

[0052] In one embodiment, the linking arm D is an alkylene chaincomprising from 1 to 10 carbon atoms.

[0053] The at least one second cationic oxidation base chosen frommonobenzenic, dibenzenic and heterocyclic oxidation bases may beoptionally substituted on at least one group chosen from benzenic andheterocyclic groups.

[0054] The at least one second cationic oxidation base may be chosen,for example, from:

[0055] (i) monobenzenic para-phenylenediamines and monobenzenicparaminophenols, such as those disclosed in European Patent ApplicationNos. 968 171 and 928 289, which are incorporated herein by reference;

[0056] (ii) dibenzenic para-phenylenediamines and dibenzenicpara-aminophenols, such as those disclosed in European PatentApplicationNo. 932 602, which is incorporated herein by reference;

[0057] (iii) monobenzenic ortho-phenylenediamines, such as thosedisclosed in European Patent Application Nos. 983 996 and 984 007, whichare incorporated herein by reference;

[0058] (iv) dibenzenic ortho-phenylenediamines, such as those disclosedin European Patent Application No. 984 006, which is incorporated hereinby reference;

[0059] (v) heterocyclic oxidation bases of the pyrazole type, such asthose disclosed in European Patent Application No.1 147 090, which isincorporated hereinby reference; and

[0060] (vi) heterocyclic oxidation bases of thepyrazolo[1,5-a]pyrimidine type, such as those disclosed in EuropeanPatent Application 1 147 109, which is incorporated herein by reference.

[0061] The monobenzenic para-phenylenediamines and monobenzenicparaminophenols may be chosen from:

[0062] [2-(2,5-diaminophenoxy)ethyl]diethylmethylammonium chloride;

[0063] N,N-bis(trimethylammoniumpropyl)-4-aminoaniline dichloride;

[0064] [4-(4-aminophenylamino)pentyl]diethylmethylammonium chloride;

[0065] [4-(4-aminophenylamino)pentyl]diethyl-(2-hydroxyethyl)ammoniumchloride;

[0066] [2-(4-aminophenylamino)ethyl]diethylmethylammonium chloride;

[0067] {2-[(4-aminophenyl)methylamino]ethyl}trimethylammonium chloride;

[0068] [3-(4-aminophenylamino)propyl]trimethylammonium chloride;

[0069] [2-(4-aminophenylamino)propyl]trimethylammonium chloride;

[0070] [4-(4-amino-2-methylphenylamino)pentyl]diethylmethylammoniumchloride;

[0071] [4-(4-amino-3-methylphenylamino)pentyl]diethyl methylammoniumchloride;

[0072]1-{[5-amino-2-(2-hydroxyethylamino)phenylcarbamoyl]methyl}-1,4-dimethylpiperazin-1-iumchloride;

[0073] 1-[2-(4-aminophenylamino)ethyl]-3-methyl-3H-imidazol-1-iumbromide;

[0074] 1-[3-(2,5-diaminophenoxy)propyl]-3-methyl-3H-imidazol-1-iumchloride;

[0075] 3-[3-(4-aminophenylamino)propyl]-1-methyl-3H-imidazol-1-iumchloride;

[0076]3-[3-(4-amino-3-methylphenylamino)propyl]-1-methyl-3H-imidazol-1-iumchloride;

[0077]3-[3-(4-amino-2-methylphenylamino)propyl]-1-methyl-3H-imidazol-1-iumchloride;

[0078]3-[3-(4-amino-2-fluorophenylamino)propyl]-1-methyl-3H-imidazol-1-iumchloride;

[0079]3-[3-(4-amino-2-cyanophenylamino)propyl]-1-methyl-3H-imidazol-1-iumchloride;

[0080]1-[2-(4-amino-2-methoxyphenylamino)ethyl]-3-methyl-3H-imidazol-1-iumchloride;

[0081] 1-(5-amino-2-hydroxybenzyl)-3-methyl-3H-imidazol-1-ium chloride;

[0082] 1-(5-amino-2-hydroxybenzyl)-2-methyl-2H-pyrazol-1-ium chloride;

[0083] 1-[2-(2,5-diaminophenyl)ethyl]-3-methyl-3H-imidazol-1-iumchloride;

[0084] 3-[2-(2,5-diaminophenyl)ethyl]-1-methyl-3H-imidazol-1-iumchloride;

[0085] 1-{2-[(4-aminophenyl)ethylamino]ethyl}-3-methyl-3H-imidazol-1-iumchloride;

[0086] N,N-bis[2-(3-methyl-3H-imidazol-1-ium)ethyl]-4-aminoanilinedichloride;

[0087] 3-[2-(4-aminophenylamino)butyl]-1-methyl-3H-imidazol-1-iumchloride;

[0088]1-{[5-amino-2-(2-hydroxyethylamino)phenylcarbamoyl]methyl}-3-methyl-3H-imidazol-1-iumchloride;

[0089] 4-[2-(2,5-diaminophenoxy)ethyl]-1,3-dimethyl-3H-imidazol-1-iumbromide;

[0090] 2-(2,5-diaminophenoxymethyl)-1,3-dimethyl-3H-imidazol-1-iumchloride;

[0091] 4-[3-(4-aminophenylamino)propyl]-1,3-dimethyl-3H-imidazol-1-iumchloride;

[0092]4-[3-(4-amino-3-methylphenylamino)propyl]-1,3-dimethyl-3H-imidazol-1-iumchloride;

[0093]4-[(2,5-diaminophenylcarbamoyl)methyl]-1,3-dimethyl-3H-imidazol-1-iumchloride;

[0094]4-{2-[2-(2-amino-5-hydroxyphenyl)acetylamino]ethyl}-1,3-dimethyl-3H-imidazol-1-iumchloride;

[0095]4-[(5-amino-2-hydroxybenzylcarbamoyl)methyl]-1,3-dimethyl-3H-imidazol-1-iumchloride;

[0096] and the addition salts thereof.

[0097] The monobenzenic para-phenylenediamines and monobenzenicparaminophenols may, for example, be chosen from:

[0098] [2-(2,5-diaminophenoxy)ethyl]diethylmethylammonium chloride;

[0099] N,N-bis(trimethylammoniumpropyl)-4-aminoaniline chloride;

[0100] [4-(4-aminophenylamino)pentyl]diethylmethylammonium chloride;

[0101] [2-(4-aminophenylamino)ethyl]diethylmethylammonium chloride;

[0102] {2-[(4-aminophenyl)methylamino]ethyl}trimethylammonium chloride;

[0103] [3-(4-aminophenylamino)propyl]trimethylammonium chloride;

[0104] [4-(4-aminophenylamino)pentyl]diethyl-(2-hydroxyethyl)ammoniumchloride;

[0105] 3-[3-(4-aminophenylamino)propyl]-1-methyl-3H-imidazol-1-iumchloride;

[0106] 1-[3-(2,5-diaminophenoxy)propyl]-3-methyl-3H-imidazol-1-iumchloride;

[0107]3-[3-(4-amino-3-methylphenylamino)propyl]-1-methyl-3H-imidazol-1-iumchloride;

[0108]3-[3-(4-amino-2-methylphenylamino)propyl]-1-methyl-3H-imidazol-1-iumchloride;

[0109]1-[2-(4-amino-2-methoxyphenylamino)ethyl]-3-methyl-3H-imidazol-1-iumchloride;

[0110]3-[3-(4-amino-2-fluorophenylamino)propyl]-1-methyl-3H-imidazol-1-iumchloride;

[0111]3-[3-(4-amino-2-cyanophenylamino)propyl]-1-methyl-3H-imidazol-1-iumchloride and the addition salts thereof.

[0112] The dibenzenic para-phenylenediamines and dibenzenicpara-aminophenols may be chosen from:

[0113]1,3-bis-1{3{3′[(4″-amino-3″-methylaniline)-N-propyl]}-3H-imidazol-1-ium}propanedichloride;

[0114]1,3-bis-1{3{3′[(4″-amino-2″-methylaniline)-N-propyl]}-3H-imidazol-1-ium}propanedichloride;

[0115]1,3-bis-1{3{3′[(4″-aminoaniline)-N-propyl]}-3H-imidazol-1-ium}propanedichloride;

[0116]1,3-bis-1{3{3′[(4″-aminoaniline)-N-propyl]}-3H-imidazol-1-ium}-2-propanoldichloride;

[0117]N₁,N₃-bis-[3-N-(4′-aminoaniline)propyl]-1,1,3,3-tetramethyl-1,3-diammoniumpropanedibromide;

[0118]1,4-bis-1{3[3-(2,5-diaminophenoxy)propyl]-3H-imidazol-1-ium)butanedichloride;

[0119] 1,3-bis[3-(2,5-diaminophenoxy)propyl]-3H-imidazol-1-iummonochloride;

[0120] N₁N₄-bis-[3-N-methyl-N-(4′-aminoaniline)ethyl]-1,1,4,4-tetramethyl-1,3-diammoniumpropane dibromide;

[0121] 1,4-bis-1-[3-(5-amino-2-hydroxybenzyl)-3H-imidazol-1-ium]butanedichloride;

[0122]1,3-bis-{[2-(4-aminoaniline)propyl]-1,1,3,3-tetramethyldiammoniumpropanedibromide;

[0123]1,3-bis-{[4-(4-aminoaniline)pentyl]-1,1,3,3-tetramethyldiammoniumpropanedichloride;

[0124][4-(4-aminophenylamino)pentyl]-(5-amino-2-hydroxybenzyl)diethylammoniummonochloride;

[0125][2-(4-aminophenylamino)propyl]-(5-amino-2-hydroxybenzyl)dimethylammoniummonochloride;

[0126]1,3-bis-1-{3-[3-(2,5-diaminophenoxy)propyl]-3H-imidazol-1-ium}propanedichloride;

[0127] 1,3-bis-1{3{3′[(4″-aminoaniline)-N-propyl]}-3H-imidazol-1-ium}propane dichloride;

[0128] 1,3-bis-1{4{4′(4-[3-(4″-aminophenylamino)propyl]}-1,3-dimethyl-3H-imidazol-1-ium}propanedichloride;

[0129] 1,3-bis-1{4{4′(4-[3-(4″-amino-2″-methylaniline)propyl]}-1,3-dimethyl-3H-imidazol-1-ium}propanedichloride;

[0130]4-[2-(2,5-diaminophenoxy)ethyl]-3-[3-(2,5-diaminophenoxy)propyl]-1-methyl-3-imidazol-1-iummonochloride;

[0131]4-[2-(2,5-diaminophenoxy)ethyl]-1′-[3-(2,5-diaminophenoxy)propyl]-3-methyl-3-imidazol-1-iummonochloride;

[0132] and the addition salts thereof.

[0133] The dibenzenic para-phenylenediamines and dibenzenicpara-aminophenols may be chosen, for example, from:

[0134] 1,3-bis-1{3{3′[(4″-aminoaniline)-N-propyl]}-3H-imidazol-1-ium}propane dichloride;

[0135] 1,3-bis[3-(2,5-diaminophenoxy)propyl]-3H-imidazol-1-iummonochloride;

[0136]N₁,N₄-bis-[3-N-methyl-N-(4′-aminoaniline)ethyl]-1,1,4,4-tetramethyl-1,3-diammoniumpropanedibromide;

[0137] 1,4-bis-1-[3-(5-amino-2-hydroxybenzyl)-3H-imidazol-1-ium]butanedichloride;

[0138] 1,3-bis-1{3{3′[(4″-aminoaniline)-N-propyl]}-3H-imidazol-1-ium}propane dichloride;

[0139] and the addition salts thereof.

[0140] The monobenzenic ortho-phenylenediamines may be chosen from:

[0141] {2-[2-aminophenylamino]ethyl}trimethylammonium monochloride;

[0142] [2-(2-amino-5-chlorophenylamino)ethyl]trimethylammoniummonochloride;

[0143] [2-(2-amino-6-chlorophenylamino)ethyl]trimethylammoniummonochloride;

[0144] [2-(2-amino-4-chlorophenylamino)ethyl]trimethylammoniummonochloride;

[0145]{2-[2-amino-4-chloro-5-(2-hydroxyethoxy)phenylamino]ethyl}trimethylammoniummonochloride;

[0146] [2-(2-amino-5-methoxyphenylamino)ethyl]trimethylammoniummonochloride;

[0147] [2-(2-aminophenylamino)ethyl]-(2-hydroxyethyl)dimethylammoniummonobromide;

[0148] 4-[2-(2-aminophenylamino)ethyl]-4-methylmorpholin-4-iummonochloride;

[0149] 1-[2-(2-aminophenylamino)ethyl]-1-ethylpiperidinium monochloride;

[0150] 1-[2-(2-aminophenylamino)ethyl]-1,4-dimethylpiperazin-1-iummonochloride;

[0151] 4-[2-(-1-methyl piperidinium)ethoxy]-N-2-[2-(1-methylpiperidinium)ethyl]benzene-1,2-diamine dichloride;

[0152]1-[2-(2-amino-5-methylsulphanylphenylamino)ethyl]-1-methylpiperidiniummonochloride;

[0153] 1-[2-(2-aminophenylamino)ethyl]-1-methylpyrrolidiniummonochloride;

[0154] [3-(2-aminophenylamino)propyl]diethylmethylammonium monochloride;

[0155] N,N′-bis-[2-(1-methylpiperidinium)ethyl]benzene-1,2-diaminedichloride;

[0156] [2-(2-amino-4-methylphenylamino)ethyl]trimethyl [lacuna]monochloride;

[0157] 3-[3-(2-aminophenylamino)propyl]-1-methyl-3H-imidazol-1-iummonochloride;

[0158] 3-[2-(2-aminophenylamino)ethyl]-1-methyl-3H-imidazol-1-iummonochloride;

[0159]4-[2-(1-methyl-3H-imidazol-1-ium)ethoxy]-N-2-[2-(1-methyl-3H-imidazol-1-ium)ethyl]benzene-1,2-diaminedichloride;

[0160]3-[2-(2-amino-4-methylphenylamino)ethyl]-1-ethyl-3H-imidazol-1-iummonochloride;

[0161]3-[3-(2-aminophenylamino)propyl]-1-(3-trimethylammonium-2-hydroxypropyl)-3H-imidazol-1-iumdichloride;

[0162]3-[3-(2-aminophenylamino)propyl]-1-(2-hydroxyethyl)-3H-imidazol-1-iummonobromide;

[0163]3-{[2-(2-aminophenylamino)ethylcarbamoyl]methyl}-1-methyl-3H-imidazol-1-iummonochloride;

[0164] 1-[2-(2-amino-4-chlorophenylamino)ethyl]pyridinium monochloride;

[0165]3-[2-(2-amino-5-methoxyphenylamino)ethyl]-1-methyl-3H-imidazol-1-iummonochloride;

[0166]3-[2-(2-amino-5-methylsulphanylphenylamino)ethyl-1-methyl-3H-imidazol-1-iummonochloride;

[0167] and the addition salts thereof.

[0168] The monobenzenic ortho-phenylenediamines may be chosen, forexample, from:

[0169] {2-[2-aminophenylamino]ethyl}trimethylammonium chloride;

[0170] 3-[3-(2-aminophenylamino)propyl]-1-methyl-3H-imidazol-1-iumchloride; and the addition salts thereof.

[0171] The dibenzenic ortho-phenylenediamines may be chosen from:

[0172]1,3-bis-{3-{3-[(2-aminoaniline)-N-propyl]}-3H-imidazol-1-ium}propanedibromide;

[0173]N₁,N₃-bis-[3-N-(2-aminoaniline)propyl]-1,1,3,3-tetramethyl-1,3-diammoniumpropanedibromide;

[0174]1,4-bis-{3-{2-[(2-aminoaniline)-N-ethyl]}-3H-imidazol-1-ium}butanedichloride;

[0175]1-[2-(2-aminoaniline)ethyl]-3-[3-(2-aminoaniline)propyl]-3H-imidazol-1-iummonochloride;

[0176] and the addition salts thereof.

[0177] The dibenzenic ortho-phenylenediamines may, for example, bechosen from:

[0178]1,3-bis-1-{3-{3-[(2-aminoaniline)-N-propyl]}-3H-imidazol-1-ium}propanedibromide;

[0179]N₁,N₃-bis-[3-N-(2-aminoaniline)propyl]-1,1,3,3-tetramethyl-1,3-diammoniumpropanedibromide; and the addition salts thereof.

[0180] The heterocyclic oxidation bases of the pyrazole type may bechosen from:

[0181][3-(4-amino-2,5-dimethyl-2H-pyrazol-3-ylamino)propyl]trimethylammoniumchloride;

[0182][3-(4-amino-2,5-dimethyl-2H-pyrazol-3-ylamino)propyl]-(2-hydroxyethyl)dimethylammoniumchloride;

[0183]3-[3-(4-amino-2,5-dimethyl-2H-pyrazol-3-ylamino)propyl]-1-(2-hydroxyethyl)-3H-imidazol-1-iumchloride;

[0184]3-[(4-amino-2H-pyrazol-3-ylcarbamoyl)methyl]-1-methyl-3H-imidazol-1-iumchloride;

[0185]3-[2-(4,5-diamino-3-methylpyrazol-1-yl)ethyl]-1-methyl-3H-imidazol-1-iumchloride;

[0186] 3-[2-(4,5-diaminopyrazol-1-yl)ethyl]-1-methyl-3H-imidazol-1-iumchloride;

[0187] [2-(4,5-diamino-3-methylpyrazol-1-yl)ethyl]trimethylammoniumchloride;

[0188] [2-(4,5-diamino-pyrazol-1-yl)ethyl]trimethylammonium chloride;

[0189] [2-(4-amino-5-hydroxypyrazol-1-yl)ethyl]trimethylammoniumchloride;

[0190][2-(4-amino-5-hydroxy-3-methylpyrazol-1-yl)ethyl]trimethylammoniumchloride;

[0191][2-(4-amino-5-hydroxy-3-methylpyrazol-1-yl)ethyl]-1-methyl-3H-imidamzol—iumchloride;

[0192] 3-[2-(4-amino-5-hydroxypyrazol-1-yl)ethyl]-1-methyl-3H-imidazol-1-ium chloride;

[0193] 3-[2-(4,5-diamino-1-methyl-1H-pyrazol-3-yl)ethyl]-1-methyl-3H-imidazol-1-ium chloride;

[0194] and the addition salts thereof, and the possible tautomeric formsthereof.

[0195] The heterocyclic oxidation bases of the pyrazole type may bechosen, for example, from:

[0196][3-(4-amino-2,5-dimethyl-2H-pyrazol-3-ylamino)propyl]trimethylammoniumchloride;

[0197][3-(4-amino-2,5-dimethyl-2H-pyrazol-3-ylamino)propyl]-(2-hydroxyethyl)dimethylammoniumchloride;

[0198]3-[3-(4-amino-2,5-dimethyl-2H-pyrazol-3-ylamino)propyl]-1-(2-hydroxyethyl)-3H-imidazol-1-iumchloride;

[0199]3-[(4-amino-2H-pyrazol-3-ylcarbamoyl)methyl]-1-methyl-3H-imidazol-1-iumchloride;

[0200]3-[2-(4,5-diamino-3-methylpyrazol-1-yl)ethyl]-1-methyl-3H-imidazol-1-iumchloride;

[0201]3-[2-(4,5-diamino-1-methyl-1H-pyrazol-3-yl)ethyl]-1-methyl-3H-imidazol-1-iumchloride,

[0202] and the addition salts thereof, and the possible tautomeric formsthereof.

[0203] The heterocyclic oxidation bases of the pyrazolo[1,5-a]pyrimidinetype may be chosen from:

[0204]1-[3-(3-amino-5,6-dimethylpyrazolo[1,5-a]pyrimidin-7-ylamino)propyl]-3-methyl-3H-imidazol-1-iummonobromide,

[0205]3-[3-(3-amino-5-methylpyrazolo[1,5-a]pyrimidin-7-ylamino)propyl]-1-(2-hydroxyethyl)-3H-imidazol-1-iumchloride,

[0206]3-[(3-aminopyrazolo[1,5-a]pyrimidin-7-ylcarbamoyl)methyl]-1-methyl-3H-imidazol-1-iumchloride,

[0207]3-(3-amino-7-hydroxy-5-methylpyrazolo[1,5-a]pyrimidin-6-ylmethyl)-1-methylpyridiniummethyl sulphate,

[0208]3-(3-amino-7-hydroxy-5-methylpyrazolo[1,5-a]pyrimidin-6-ylmethyl)-1-(2-hydroxyethyl)pyridiniumchloride,

[0209]2-[(3-aminopyrazolo[1,5-a]pyrimidin-7-ylamino)methyl]-1,3-dimethyl-3H-imidazol-1-iummethyl sulphate,

[0210]3-[(3-aminopyrazolo[1,5-a]pyrimidin-7-ylamino)methyl]-1-methylpyridiniummethyl sulphate,

[0211]3-[(3-aminopyrazolo[1,5-a]pyrimidin-7-ylamino)methyl]-1-methylpyridiniummethyl sulphate,

[0212] 2-(3,7-diamino-5-methylpyrazolo[1,5-a]pyri midin-6-ylmethyl]-1,3-dimethyl-3H-imidazol-1-ium methyl sulphate,

[0213]2-(3-amino-7-hydroxy-5-methylpyrazolo[1,5-a]pyrimidin-6-ylmethyl)-1,3-dimethyl-3H-imidazol-1-iummethyl sulphate,

[0214] 2-(3,7-diaminopyrazolo[1,5-a]pyrimidin-2-yl)-1-methylpyridiniummethyl sulphate,

[0215][3-(3-amino-5-methylpyrazolo[1,5-a]pyrimidin-7-ylamino)propyl]trimethylammoniumchloride,

[0216][3-(3-amino-5-methylpyrazolo[1,5-a]pyrimidin-7-ylamino)propyl]trimethylammoniummethyl sulphate,

[0217]1-[3-(3-amino-5-methylpyrazolo[1,5-a]pyrimidin-7-ylamino)propyl]-1-methylpiperidiniumchloride,

[0218]1-[3-(3-amino-5-methylpyrazolo[1,5-a]pyrimidin-7-ylamino)propyl]-1-methylpiperidinium methyl sulphate,

[0219]4-[3-(3-amino-5-methylpyrazolo[1,5-a]pyrimidin-7-ylamino)propyl]-4-methylmorpholin-4-iumchloride,

[0220]4-[3-(3-amino-5-methylpyrazolo[1,5-a]pyrimidin-7-ylamino)propyl]-4-methylmorpholin-4-iummethyl sulphate,

[0221] and the addition salts thereof.

[0222] The heterocyclic oxidation bases of the pyrazolo[1,5-a]pyrimidinetype may, for example, be chosen from:

[0223]1-[3-(3-amino-5,6-dimethylpyrazolo[1,5-a]pyrimidin-7-ylamino)propyl]-3-methyl-3H-imidazol-1-iummonobromide,

[0224]3-[3-(3-amino-5-methylpyrazolo[1,5-a]pyrimidin-7-ylamino)propyl]-1-(2-hydroxyethyl)-3H-imidazol-1-iumchloride,

[0225]3-(3-amino-7-hydroxy-5-methylpyrazolo[1,5-a]pyrimidin-6-ylmethyl)-1-methylpyridiniummethyl sulphate,

[0226]3-(3-amino-7-hydroxy-5-methylpyrazolo[1,5-a]pyrimidin-6-ylmethyl)-1-(2-hydroxyethyl)pyridiniumchloride,

[0227]3-(3-amino-7-hydroxy-5-methylpyrazolo[1,5-a]pyrimidin-6-ylmethyl)-1-methylpyridiniumchloride,

[0228]4-[3-(3-amino-5-methylpyrazolo[1,5-a]pyrimidin-7-ylamino)propyl]-4-methylmorpholin-4-iumchloride,

[0229]4-[3-(3-amino-5-methylpyrazolo[1,5-a]pyrimidin-7-ylamino)propyl]-4-methylmorpholin-4-iummethyl sulphate,

[0230] and the addition salts thereof.

[0231] The at least one second cationic oxidation base chosen frommonobenzenic para-phenylenediamines such as1,3-bis[3-(2,5-diaminophenoxy)propyl]-3H-imidazol-1-ium monochloridetetrahydrochloride monohydrate may also be used.

[0232] The at least one coupler used in the composition disclosed hereinmay be chosen from couplers conventionally used in the field of dyeing.The at least one coupler may be chosen, for example, frommeta-phenylenediamines, meta-aminophenols, metadiphenols, naphthaleniccouplers and heterocyclic couplers, and the addition salts thereof.

[0233] The at least one coupler may be chosen, for example, from2-methyl-5-aminophenol, 5-N-(β-hydroxyethyl)amino-2-methylphenol,6-chloro-2-methyl-5-aminophenol, 3-aminophenol, 1,3-dihydroxybenzene,1,3-dihydroxy-2-methylbenzene, 4-chloro-1,3-dihydroxybenzene,2,4-diamino-1-(β-hydroxyethyloxy)benzene,2-amino-4-(β-hydroxyethylamino)-1-methoxybenzene, 1,3-diaminobenzene,1,3-bis(2,4-diaminophenoxy)propane, 3-ureidoaniline,3-ureido-1-dimethylaminobenzene, sesamol,1β-hydroxyethylamino-3,4-methylenedioxybenzene, α-naphthol,2-methyl-1-naphthol, 6-hydroxyindole, 4-hydroxyindole,4-hydroxy-N-methylindole, 2-amino-3-hydroxypyridine,6-hydroxybenzomorpholine, 3,5-diamino-2,6-dimethoxypyridine,1-N-(β-hydroxyethyl)amino-3,4-methylened ioxybenzene,2,6-bis(β-hydroxyethylamino)toluene and the addition salts thereof.

[0234] In one embodiment, the at least one coupler may be present in anamount ranging from 0.001% to 10% by weight, relative to the totalweight of the dye composition, such as from 0.005% to 6% by weight,relative to the total weight of the dye composition.

[0235] The composition disclosed herein may, for example, furthercomprise at least one additional non-cationic oxidation base chosen fromthose conventionally used in oxidation dyeing, other than the at leastone first oxidation base chosen from 4,5-diaminopyrazole derivatives offormula (I) disclosed above. The at least one additional non-cationicoxidation base may be chosen, for example, from para-phenylenediaminesother than those described above, bis(phenyl)alkylenediamines,para-aminophenols, orthoaminophenols, heterocyclic bases other thanthose described above, and the addition salts thereof.

[0236] The para-phenylenediamines other than those described above maybe chosen, for example, from para-phenylenediamine,para-tolylenediamine, 2-chloro-para-phenylenediamine,2,3-dimethyl-para-phenylenediamine, 2,6-dimethyl-para-phenylenediamine,2,6-diethyl-para-phenylenediamine, 2,5-dimethyl-para-phenylenediamine,N,N-dimethyl-para-phenylenediamine, N,N-diethyl-para-phenylenediamine,N,N-dipropyl-para-phenylenediamine, 4-amino-N,N-diethyl-3-methylaniline,N,N-bis(β-hydroxyethyl)-para-phenylenediamine,4-N,N-bis(β-hydroxyethyl)amino-2-methylaniline,4-N,N-bis(β-hydroxyethyl)amino-2-chloroaniline,2-β-hydroxyethyl-para-phenylenediamine, 2-fluoro-para-phenylenediamine,2-isopropyl-paraphenylenediamine,N-(β-hydroxypropyl)-para-phenylenediamine,2-hydroxymethyl-para-phenylenediamine,N,N-dimethyl-3-methyl-para-phenylenediamine,N-ethyl-N-(β-hydroxyethyl)-para-phenylenediamine,N-(β,γ-dihydroxypropyl)-para-phenylenediamine,N-(4′-aminophenyl)-para-phenylenediamine,N-phenyl-para-phenylenediamine,2-β-hydroxyethyloxy-para-phenylenediamine, 2-β-acetylaminoethyloxy-para-phenylenediamine,N-(β-methoxyethyl)-para-phenylenediamine,2-thienyl-para-phenylenediamine and2-β-hydroxyethylamino-5-aminotoluene, and the addition salts thereof.

[0237] The para-phenylenediamines may also be chosen, for example, fromparaphenylenediamine, para-tolylenediamine,2-isopropyl-para-phenylenediamine,2-β-hydroxyethyl-para-phenylenediamine,2-β-hydroxyethyloxy-para-phenylenediamine,2,6-dimethyl-para-phenylenediamine, 2,6-diethyl-para-phenylenediamine,2,3-dimethyl-para-phenylenediamine,N,N-bis(β-hydroxyethyl)-para-phenylenediamine,2-chloro-paraphenylenediamine,2-β-acetylaminoethyloxy-para-phenylenediamine, and the addition saltsthereof, such as acid addition salts thereof.

[0238] The bis(phenyl)alkylenediamines may be chosen, for example, fromN,N′-bis(β-hydroxyethyl)-N,N′-bis(4′-aminophenyl)-1,3-diaminopropanol,N,N′-bis(β-hydroxyethyl)-N,N′-bis(4′-aminophenyl)ethylenediamine,N,N′-bis(4-aminophenyl)tetramethylenediamine,N,N′-bis(β-hydroxyethyl)-N,N′-bis(4-aminophenyl)tetramethylenediamine,N,N′-bis(4-methylaminophenyl)tetramethylenediamine,N,N′-bis(ethyl)-N,N′-bis(4′-amino-3′methylphenyl)ethylenediamine,1,8-bis(2,5-diaminophenoxy)-3,6-dioxaoctane, and the addition saltsthereof.

[0239] The para-aminophenols may be chosen, for example, frompara-aminophenol, 4-amino-3-methylphenol, 4-amino-3-fluorophenol,4-amino-3-hydroxymethylphenol, 4-amino-2-methylphenol,4-amino-2-hydroxymethylphenol, 4-amino-2-methoxymethylphenol,4-amino-2-aminomethylphenol,4-amino-2-(β-hydroxyethylaminbmethyl)phenol, 4-amino-2-fluorophenol, andthe addition salts thereof.

[0240] The ortho-aminophenols may be chosen, for example, from2-aminophenol, 2-amino-5-methylphenol, 2-amino-6-methylphenol,5-acetamido-2-aminophenol, and the addition salts thereof.

[0241] The heterocyclic bases, other than those described above, may bechosen, for example, from pyridine derivatives, pyrimidine derivativesand pyrazole derivatives, other than those described above.

[0242] The pyridine derivatives may be chosen, for example, from thecompounds disclosed in Patent Nos. GB 1 026 978 and GB 1 153 196, suchas 2,5-diaminopyridine, 2-(4-methoxyphenyl)amino-3-aminopyridine,2,3-diamino-6-methoxypyridine,2-(β-methoxyethyl)amino-3-amino-6-methoxypyridine, 3,4-diaminopyridine,and the addition salts thereof.

[0243] Other pyridine oxidation bases may be chosen, for example, from3-aminopyrazolo[1,5-a]pyridine oxidation bases and the addition saltsthereof disclosed, for example, in patent application FR 2 801 308, suchas, for example, pyridine oxidation bases chosen frompyrazolo[1,5-a]pyrid-3-ylamine;2-acetylaminopyrazolo[1,5-a]pyrid-3-ylamine;2-morpholin-4-ylpyrazolo[1,5-a]pyrid-3-ylamine;3-aminopyrazolo[1,5-a]pyridine-2-carboxylic acid,2-methoxypyrazolo[1,5-a]pyrid-3-ylamine;(3-aminopyrazolo[1,5-a]pyrid-7-yl)methanol;2-(3-aminopyrazolo[1,5-a]pyrid-5-yl)ethanol;2,3-aminopyrazolo[1,5-a]pyrid-7-yl)ethanol;(3-aminopyrazolo[1,5-a]pyrid-2-yl)methanol;3,6-diaminopyrazolo[1,5-a]pyridine; 3,4-diaminopyrazolo[1,5-a]pyridine;pyrazolo[1,5-a]pyridine-3,7-diamine;7-morpholin-4-ylpyrazolo[1,5-a]pyrid-3-ylamine;pyrazolo[1,5-a]pyridine-3,5-diamine;5-morpholin-4-ylpyrazolo[1,5-a]pyrid-3-ylamine;2-[(3-aminopyrazolo[1,5-a]pyrid-5-yl)(2-hydroxyethyl)amino]ethanol;2-[(3-aminopyrazolo[1,5-a]pyrid-7-yl)(2-hydroxyethyl)amino]ethanol;3-aminopyrazolo[1,5-a]pyrid-5-ol; 3-aminopyrazolo[1,5-a]pyrid-4-ol;3-aminopyrazolo[1,5-a]pyrid-6-ol; 3-aminopyrazolo[1,5-a]pyrid-7-ol andthe addition salts thereof.

[0244] The pyrimidine derivatives may be chosen, for example, from thecompounds disclosed, for example, in Patent Nos. DE 2 359 399, JP 88-169571; JP 05 163 124; and EP 0 770 375; and Patent Application No. WO96/15765, such as 2,4,5,6-tetraminopyrimidine,4-hydroxy-2,5,6-triaminopyrimidine, 2-hydroxy-4,5,6-triaminopyrimidine,2,4-dihydroxy-5,6-diaminopyrimidine and 2,5,6-triaminopyrimidine, andpyrazolopyrimidine derivatives which may be chosen, for example, fromthose disclosed in Patent Application No. FR-A-2 750 048, such aspyrazolo[1,5-a]pyrimidine-3,7-diamine;2,5-dimethylpyrazolo[1,5-a]pyrimidine-3,7-diamine;pyrazolo[1,5-a]pyrimidine-3,5-diamine;2,7-dimethylpyrazolo[1,5-a]pyrimidine-3,5-diamine;3-aminopyrazolo[1,5-a]pyrimidin-7-ol;3-aminopyrazolo[1,5-a]pyrimidin-5-ol;2-(3-aminopyrazolo[1,5-a]pyrimidin-7-ylamino)ethanol,2-(7-aminopyrazolo[1,5-a]pyrimidin-3-ylamino)ethanol,2-[(3-aminopyrazolo[1,5-a]pyrimidin-7-yl)(2-hydroxyethyl)amino]ethanol,2-[(7-aminopyrazolo[1,5-a]pyrimidin-3-yl)(2-hydroxyethyl)amino]ethanol,5,6-dimethylpyrazolo[1,5-a]pyrimidine-3,7-diamine,2,6-dimethylpyrazolo[1,5-a]pyrimidine-3,7-diamine,2,5,N7,N7-tetramethylpyrazolo[1,5-a]pyrimidine-3,7-diamine,3-amino-5-methyl-7-imidazolylpropylamino-pyrazolo[1,5-a]pyrimidine, andthe addition salts thereof and the tautomeric forms thereof, where atautomeric equilibrium exists.

[0245] The pyrazole derivatives may be chosen, for example, from thecompounds disclosed in Patent Nos. DE 3 843 892 and DE 4 133 957 andPatent Application Nos. WO 94/08969, WO 94/08970, FR-A-2 733 749 and DE195 43 988, such as 4,5-diamino-1-methylpyrazole,4,5-diamino-1-(β-hydroxyethyl)pyrazole, 3,4-diaminopyrazole,4,5-diamino-1-(4′-chlorobenzyl)pyrazole,4,5-diamino-1,3-dimethylpyrazole, 4,5-diamino-3-methyl-1-phenylpyrazole,4,5-diamino-1-methyl-3-phenylpyrazole,4-amino-1,3-dimethyl-5-hydrazinopyrazole,1-benzyl-4,5-diamino-3-methylpyrazole,4,5-diamino-3-tert-butyl-1-methylpyrazole,4,5-diamino-1-tert-butyl-3-methylpyrazole,4,5-diamino-1-(β-hydroxyethyl)-3-methylpyrazole,4,5-diamino-1-ethyl-3-methylpyrazole,4,5-diamino-1-ethyl-3-(4′-methoxyphenyl)pyrazole,4,5-diamino-1-ethyl-3-hydroxymethylpyrazole,4,5-diamino-3-hydroxymethyl-1-methylpyrazole,4,5-diamino-3-hydroxymethyl-1-isopropylpyrazole,4,5-diamino-3-methyl-1-isopropylpyrazole,4-amino-5-(2′-aminoethyl)amino-1,3-dimethylpyrazole,3,4,5-triaminopyrazole, 1-methyl-3,4,5-triaminopyrazole, 3,5-diamino-1methyl-4-methylaminopyrazole,3,5-diamino-4-(P-hydroxyethyl)amino-1-methylpyrazole, and the additionsalts thereof.

[0246] The oxidation bases present in the composition may each presentin an amount ranging, for example, from 0.001% to 10% by weight,relative to the total weight of the dye composition, such as from 0.005%to 6% by weight, relative to the total weight of the dye composition.

[0247] The addition salts of the oxidation bases and of the at least onecoupler may be chosen, for example, from the acid addition salts, suchas hydrochlorides, hydrobromides, sulphates, citrates, succinates,tartrates, lactates, tosylates, benzenesulphonates, phosphates andacetates; and the base addition salts, such as sodium hydroxide,potassium hydroxide, ammonia, amines and alkanolamines.

[0248] In one embodiment, the dyeing composition may also comprise atleast one direct dye chosen, for example, from nitrobenzene dyes, azodirect dyes and methine direct dyes. The at least one direct dye may beof nonionic, anionic or cationic nature.

[0249] The medium suitable for dyeing, also known as the dye support,may be chosen, for example, from water and mixtures of water and atleast one organic solvent to dissolve the compounds which may not besufficiently soluble in water. The at least one organic solvent may bechosen, for example, from C₁-C₄ lower alkanols, such as ethanol andisopropanol; polyols and polyol ethers such as 2-butoxyethanol,propylene glycol, propylene glycol monomethyl ether, diethylene glycolmonoethyl ether and monomethyl ether, and aromatic alcohols such asbenzyl alcohol and phenoxyethanol.

[0250] The at least one organic solvent may be present in an amountranging, for example, from 1% to 40% by weight, relative to the totalweight of the dye composition, such as from 5% to 30% by weight,relative to the total weight of the dye composition.

[0251] The dye composition may further comprise at least one adjuvantchosen from adjuvants conventionally used in compositions for dyeing thehair, for example, anionic, cationic, nonionic, amphoteric andzwitterionic surfactants, anionic, cationic, nonionic, amphoteric andzwitterionic polymers, inorganic and organic thickeners, and forexample, anionic, cationic, nonionic and amphoteric associativepolymeric thickeners, antioxidants, penetration agents, sequesteringagents, fragrances, buffers, dispersing agents, packaging agents such asvolatile and non-volatile, modified and unmodified silicones,film-forming agents, ceramides, preserving agents and opacifiers.

[0252] The at least one adjuvant may be present in an amount ranging,for example, from 0.01% to 20% by weight, relative to the weight of thecomposition.

[0253] Needless to say, a person skilled in the art will take care toselect at least one optional additional compound such that theadvantageous properties intrinsically associated with the oxidation dyecomposition disclosed herein are not, or are not substantially,adversely affected by the addition envisaged.

[0254] The pH of the dye composition may, for example, range from 3 to12, such as from 5 to 11. The pH may be adjusted, for example, to thedesired value using at least one entity chosen from acidifying andbasifying agents usually used in the dyeing of keratin fibres andstandard buffer systems.

[0255] The acidifying agents may be chosen, for example, from inorganicand organic acids such as hydrochloric acid, orthophosphoric acid,sulphuric acid, carboxylic acids such as acetic acid, tartaric acid,citric acid and lactic acid, and sulphonic acids.

[0256] The basifying agents may be chosen, for example, from aqueousammonia, alkaline carbonates, alkanolamines, such as mono-, di- andtriethanolamines and derivatives thereof, sodium hydroxide, potassiumhydroxide and the compounds of formula (V) below:

[0257] wherein W is chosen from propylene residues optionallysubstituted with at least one radical chosen from a hydroxyl radical andC₁-C₄ alkyl radicals; R_(a), R_(b), R_(c) and R_(d), which may beidentical or different, are each chosen from hydrogen, C₁-C₄ alkylradicals and C₁-C₄ hydroxyalkyl radicals.

[0258] The dye composition disclosed herein may be in various forms,such as in a form chosen from liquids, creams and gels, and any otherform that is suitable for dyeing keratin fibres; such as human hair.

[0259] Further disclosed herein is a dyeing process, comprising applyingthe dyeing composition disclosed herein to keratin fibres. And thecolour may be developed using at least one oxidizing agent. The colourmay be developed at acidic, neutral or alkaline pH. The at least oneoxidizing agent may be mixed with the dyeing composition disclosedherein at the time of use, or an oxidizing composition comprising the atleast one oxidizing agent may be applied simultaneously or sequentiallyto the dyeing composition disclosed herein.

[0260] In one embodiment, the dyeing composition may be mixed, forexample, at the time of use, with an oxidizing composition comprising,in a medium suitable for dyeing, at least one oxidizing agent, whereinthe at least one oxidizing agent is present in an amount that issufficient to develop a coloration. The mixture obtained may then beapplied to the keratin fibres. After an action time ranging from 3 to 50minutes, for example, 5 to 30 minutes, the keratin fibres may be rinsed,washed with shampoo, rinsed again, and then dried.

[0261] The at least one oxidizing agent may be chosen, for example, fromoxidizing agents conventionally used for the oxidation dyeing of keratinfibres, for example, hydrogen peroxide, urea peroxide, alkali metalbromates, persalts such as perborates and persulphates, peracids andoxidase enzymes, such as peroxidases, 2-electron oxidoreductases such asuricases, and 4-electron oxygenases, such as laccases. In oneembodiment, the at least one oxidizing agent is hydrogen peroxide.

[0262] The oxidizing composition may further comprise, for example, atleast one adjuvant chosen, for example, from adjuvants conventionallyused in compositions for dyeing the hair, such as those defined abovefor the dye composition.

[0263] The pH of the oxidizing composition comprising the at least oneoxidizing agent may be, for example, such that after mixing with the dyecomposition, the pH of the resulting composition applied to the keratinfibres ranges from 3 to 12, such as from 5 to 11. The pH may be adjustedto the desired value, for example, by using at least one entity chosenfrom acidifying agents andbasifying agents usually used in the dyeing ofkeratin fibres, and standard buffer systems as defined above.

[0264] The ready-to-use composition that is finally applied to thekeratin fibres may be in various forms, such as in a form chosen fromliquids, creams and gels and any other form that is suitable for dyeingkeratin fibres, such as human hair.

[0265] Further disclosed herein is a multi-compartment dyeing device or“kit”, wherein a first compartment comprises the dye compositiondisclosed herein and a second compartment comprises an oxidizingcomposition. This device may be equipped, for example, with a means forapplying the desired mixture to the hair, such as the devices disclosedin French Patent No. FR-2 586 913.

[0266] The diaminopyrazole compounds that are useful in the dyecomposition disclosed herein are known compounds that may be obtained,for example, using general preparation processes known to those skilledin the art. For example, the synthetic approach shown below is disclosedin the literature up to the intermediate (2) (J. H. P. Juffermanns, C.L; Habraken; J. Org. Chem. 1986, 51, 4656; Klebe et al.; Synthesis,1973, 294; R. Hüttel, F. Büchele; Chem. Ber.; 1955, 88,1586). In thepresent case, the conversion of intermediate 3 into intermediate 4 isperformed using a R₂NH₂/EtOH mixture.

[0267] The alkylation and the amination to obtain the4,5-diaminopyrazole derivatives of formula (1) are disclosed in documentDE 42 34 885.

[0268] The examples that follow illustrate embodiments of-the presentdisclosure without, however, being limiting in nature.

EXAMPLES Example 1 Synthesis of 4,5-diamino-1-(2′-methoxyethyl)pyrazoledihydrochloride

[0269]

[0270] A mixture of5-benzylamino-3-bromo-1-(2′-methoxyethyl)-4-nitropyrazole (4 g, 2.8mmol) in ethanol (500 ml) comprising a 10% Pd/C catalyst (Johnson-MatteyType 487, dry weight 0.5 g) and 36% hydrochloric acid (0.57 g, 5.6 mmol)was hydrogenated in a Parr Autoclave (11) at 1 MPa for 1 hour. Thecatalyst was then removed by filtration and washed with ethanol, and thefiltrate was evaporated under reduced pressure. A crude orange-coloredsolid (2.8 g) was thus obtained, and was triturated in EtOAc (20 ml) for1 hour. The solid was then filtered off and washed with cold EtOAc (20ml) and then dried under vacuum to give the4,5-diamino-1-(2′-methoxyethyl)pyrazole in the form of a beige-coloredsolid (0.7 g, 27%).

[0271] HPLC (purity): 99.5%

[0272] m.p.: 168.1-173.0° C.

[0273]¹H NMR: (400 MHz, d⁶-DMSO): 7.34 (1H, s, NH_(arom)), 5.18 (1H,S_(broad), NH), 4.09 (2H, t, J=5.5 Hz, CH₂N), 3.61 (2H, t, J=5.5 Hz,CH₂O), 3.23 (3H, s, OCH₃).

Example 2 Dye Composition Comprising4,5-diamino-1-(2′-methoxyethyl)pyrazole Hydrochloride

[0274] The following dye composition was prepared: Example 24,5-Diamino-1-(2′-methoxyethyl)pyrazole 2HCl 6 × 10⁻³ mol1,3-Bis[3-(2,5-diaminophenoxy)propyl]-3H-imidazol- 2 × 10⁻³ mol 1-iummonochloride tetrahydrochloride monohydrate (oxidation base)2-Methyl-5-aminophenol (coupler) 8 × 10⁻³ mol Dye support (*)Demineralized water q.s. 100 g

[0275] At the time of use, the composition was mixed with an equalweight of 20 volumes aqueous hydrogen peroxide solution (6% by weight).

[0276] The mixture obtained was applied to locks of natural andpermanent-waved grey hair containing 90% white hairs, at a rate of 10 gper 1 g of hair. After an action time of 30 minutes, the locks wererinsed, washed with a standard shampoo, rinsed again, and then dried.

[0277] The locks were assessed visually. An intense coppery mahoganycoloration was thus obtained.

What is claimed is:
 1. A dye composition comprising, in a mediumsuitable for dyeing: at least one first oxidation base chosen from4,5-diaminopyrazole derivatives of formula (I) and the addition saltsthereof,

wherein R¹ is chosen from C₁-C₆ alkyl radicals substituted with at leastone radical chosen from OR² radicals wherein R² is chosen from C₁-C₆alkyl radicals; at least one second cationic oxidation base chosen frommonobenzenic, dibenzenic and heterocyclic oxidation bases, and theaddition salts thereof, wherein said at least one second cationicoxidation base comprises at least one cationic group Z chosen fromaliphatic chains optionally bearing at least one ring chosen fromsaturated and unsaturated rings; wherein said at least one cationicgroup Z is linked directly to at least one benzenic ring or to at leastone heterocycle of said at least one second cationic oxidation base orlinked to at least one amine functional group borne by said at least onebenzenic ring or said at least one heterocycle; and at least onecoupler.
 2. The composition according to claim 1, wherein, in definingthe at least one first oxidation base chosen from 4,5-diaminopyrazolederivatives of formula (I), R¹ is chosen from C₁-C₄ alkyl radicalssubstituted with at least one radical chosen from OR² radicals, whereinR² is chosen from C₁-C₄ alkyl radicals.
 3. The composition according toclaim 2, wherein the at least one first oxidation base is chosen from4,5-diamino-1-(2′-methoxyethyl)pyrazole and the addition salts thereof.4. The composition according to claim 1, wherein the at least onecationic group Z is chosen from unsaturated cationic groups of formulae(II) and (III) below, and saturated cationic groups of formula (IV)below:

wherein: D is a linking arm chosen from linear and branched alkylenechains comprising from 1 to 14 carbon atoms, which may be interruptedwith at least one hetero atom, and which may be substituted with atleast one radical chosen from hydroxyl and C₁-C₆ alkoxy radicals, andwhich may bear at least one ketone functional group; the ring members E,G, J, L and M, which may be identical or different, are each chosen fromcarbon, oxygen, sulphur and nitrogen atoms; n is an integer ranging from0 to 4; m is an integer ranging from 0 to 5; R and R₇ to R₁₁, which maybe identical or different, are each chosen from halogen atoms, ahydroxyl radical, amino groups, cyano groups, amido groups, SO₃X groups,aryl groups, and Z₁, OZ₁, NHZ₁, and NZ₁Z₂ radicals; two of the radicalschosen from R₈, R₉, and R₁₀ may form a 5- or 6-membered saturatedheterocycle, which may be interrupted with at least one additionalhetero atom and which may comprise at least one substituent chosen fromhydroxyl, amino, halogen, cyano, amido and CO₂X groups, C₁-C₆ alkylradicals, C₁-C₆ alkoxy radicals, C₁-C₆ monoalkylamino radicals and C₁-C₆dialkylamino radicals; Z₁ and Z₂, which may be identical or different,are each chosen from linear and branched C₁-C₁₄ hydrocarbon-basedchains, which may be interrupted with at least one hetero atom and whichmay comprise at least one substituent chosen from hydroxyl, amino,amido, halogen, cyano and CO₂X groups, C₁-C₆ alkyl radicals, C₁-C₆alkoxy radicals, C₁-C₆ monoalkylamino radicals and C₁-C₆ dialkylaminoradicals; X is chosen from hydrogen, alkali metal and alkaline-earthmetal residues, ammonium ions, C₁-C₆ alkyl radicals and residues derivedfrom an organic amine; Y⁻ is an anion chosen from monovalent anddivalent anions derived from at least one acid chosen from mineral andorganic acids; x and y are integers equal to 0 or 1; with the followingconditions: in the unsaturated cationic groups of formula (II): whenx=0, the linking arm D is attached to the nitrogen atom of theunsaturated ring, when x=1, the linking arm D is attached to one of thering members E, G, J or L y can take the value 1 only: 1) when the ringmembers E, G, J and L simultaneously are each a carbon atom, and whenthe radical R₇ is borne by the nitrogen atom of the unsaturated ring; or2) when at least one of the ring members E, G, J and L is a nitrogenatom to which the radical R₇ is attached; in the unsaturated cationicgroups of formula (III): when x=0, the linking arm D is attached to thenitrogen atom of the unsaturated ring, when x=1, the linking arm D isattached to one of the ring members E, G, J, L or M, y can take thevalue 1 only when at least one of the ring members E, G, J, L and M is adivalent atom, and when the radical R₇ is borne by the nitrogen atom ofthe unsaturated ring; in the cationic groups of formula (IV): when x=0,then the linking arm is attached to the nitrogen atom bearing theradicals R₈ to R₁₀, when x=1, then two of the radicals chosen from R₈,R₉, and R₁₀ form, together with the nitrogen atom to which they areattached, a 5- or 6-membered saturated ring, which may be optionallyinterrupted with at least one additional hetero atom and which maycomprise at least one substituent chosen from hydroxyl, amino, halogen,cyano, amido and CO₂X groups, C₁-C₆ alkyl radicals, C₁-C₆ alkoxyradicals, C₁-C₆ monoalkylamino radicals and C₁-C₆ dialkylamino radicals,and the linking arm D is borne by a carbon atom of said saturated ring.5. The composition according to claim 4, wherein the Y⁻ is an anionchosen from halogens, a hydrogen sulphate, and (C₁-C₆)alkyl sulphates.6. The composition according to claim 5, wherein the halogens are chosenfrom chlorine, bromine, fluorine, and iodine.
 7. The compositionaccording to claim 5, wherein the (C₁-C₆)alkyl sulphates are chosen frommethyl sulphate and ethyl sulphate.
 8. The composition according toclaim 4, wherein the at least one hetero atom and the at least oneadditional hetero atom are chosen from oxygen, sulphur and nitrogenatoms.
 9. The composition according to claim 4, wherein the unsaturatedring of the at least one cationic group Z of formula (II) is chosen frompyrrole, imidazole, pyrazole, oxazole, thiazole and triazole rings. 10.The composition according to claim 4, wherein the unsaturated ring ofthe at least one cationic group Z of formula (III) is chosen frompyridine, pyrimidine, pyrazine, oxazine and triazine rings.
 11. Thecomposition according to claim 4, wherein the saturated ring of the atleast one cationic group Z of formula (IV) is chosen from pyrrolidine,piperidine, piperazine and morpholine rings.
 12. The compositionaccording to claim 4, wherein the linking arm D is an alkylene chaincomprising from 1 to 10 carbon atoms.
 13. The composition according toclaim 1, wherein the at least one second cationic oxidation base ischosen from: (i) monobenzenic para-phenylenediamines and monobenzenicpara-aminophenols; (ii) dibenzenic para-phenylenediamines and dibenzenicpara-aminophenols; (iii) monobenzenic ortho-phenylenediamines; (iv)dibenzenic ortho-phenylenediamines; (v) heterocyclic oxidation bases ofthe pyrazole type; and (vi) heterocyclic oxidation bases of thepyrazolo[1,5-a]pyrimidine type.
 14. The composition according to claim13, wherein the monobenzenic paraphenylenediamines and monobenzenicpara-aminophenols are chosen from:[2-(2,5-diaminophenoxy)ethyl]diethylmethylammonium chloride;N,N-bis(trimethylammoniumpropyl)-4-aminoaniline dichloride;[4-(4-aminophenylamino)pentyl]diethylmethylammonium chloride;[4-(4-aminophenylamino)pentyl]diethyl-(2-hydroxyethyl)ammonium chloride;[2-(4-aminophenylamino)ethyl]diethylmethylammonium chloride;{2-[(4-aminophenyl)methylamino]ethyl}trimethylammonium chloride;[3-(4-aminophenylamino)propyl]trimethylammonium chloride;[2-(4-aminophenylamino)propyl]trimethylammonium chloride;[4-(4-amino-2-methylphenylamino)pentyl]diethylmethylammonium chloride;[4-(4-amino-3-methylphenylamino)pentyl]diethylmethylammonium chloride;1-{[5-amino-2-(2-hydroxyethylamino)phenylcarbamoyl]methyl}-1,4-dimethylpiperazin-1-iumchloride; 1-[2-(4-aminophenylamino)ethyl]-3-methyl-3H-imidazol-1-iumbromide; 1-[3-(2,5-diaminophenoxy)propyl]-3-methyl-3H-imidazol-1-iumchloride; 3-[3-(4-aminophenylamino)propyl]-1-methyl-3H-imidazol-1-iumchloride;3-[3-(4-amino-3-methylphenylamino)propyl]-1-methyl-3H-imidazol-1-iumchloride;3-[3-(4-amino-2-methylphenylamino)propyl]-1-methyl-3H-imidazol-1-iumchloride;3-[3-(4-amino-2-fluorophenylamino)propyl]-1-methyl-3H-imidazol-1-iumchloride;3-[3-(4-amino-2-cyanophenylamino)propyl]-1-methyl-3H-imidazol-1-iumchloride;1-[2-(4-amino-2-methoxyphenylamino)ethyl]-3-methyl-3H-imidazol-1-iumchloride; 1-(5-amino-2-hydroxybenzyl)-3-methyl-3H-imidazol-1-iumchloride; 1-(5-amino-2-hydroxybenzyl)-2-methyl-2H-pyrazol-1-iumchloride; 1-[2-(2,5-diaminophenyl)ethyl]-3-methyl-3H-imidazol-1-iumchloride; 3-[2-(2,5-diaminophenyl)ethyl]-1-methyl-3H-imidazol-1-iumchloride;1-{2-[(4-aminophenyl)ethylamino]ethyl}-3-methyl-3H-imidazol-1-iumchloride; N,N-bis[2-(3-methyl-3H-imidazol-1-ium)ethyl]-4-aminoanilinedichloride; 3-[2-(4-aminophenylamino)butyl]-1-methyl-3H-imidazol-1-iumchloride;1-{[5-amino-2-(2-hydroxyethylamino)phenylcarbamoyl]methyl}-3-methyl-3H-imidazol-1-iumchloride; 4-[2-(2,5-diaminophenoxy)ethyl]-1,3-dimethyl-3H-imidazol-1-iumbromide; 2-(2,5-diaminophenoxymethyl)-1,3-dimethyl-3H-imidazol-1-iumchloride;4-[3-(4-aminophenylamino)propyl]-1,3-dimethyl-3H-imidazol-1-iumchloride;4-[3-(4-amino-3-methylphenylamino)propyl]-1,3-dimethyl-3H-imidazol-1-iumchloride;4-[(2,5-diaminophenylcarbamoyl)methyl]-1,3-dimethyl-3H-imidazol-1-iumchloride;4-{2-[2-(2-amino-5-hydroxyphenyl)acetylamino]ethyl}-1,3-dimethyl-3H-imidazol-1-iumchloride;4-[(5-amino-2-hydroxybenzylcarbamoyl)methyl]-1,3-dimethyl-3H-imidazol-1-iumchloride; and the addition salts thereof.
 15. The composition accordingto claim 14, wherein the monobenzenic paraphenylenediamines andmonobenzenic para-aminophenols are chosen from:[2-(2,5-diaminophenoxy)ethyl]diethylmethylammonium chloride;N,N-bis(trimethylammoniumpropyl)-4-aminoaniline chloride;[4-(4-aminophenylamino)pentyl]diethylmethylammonium chloride;[2-(4-aminophenylamino)ethyl]diethylmethylammonium chloride;{2-[(4-aminophenyl)methylamino]ethyl}trimethylammonium chloride;[3-(4-aminophenylamino)propyl]trimethylammonium chloride;[4-(4-aminophenylamino)pentyl]diethyl-(2-hydroxyethyl)ammonium chloride;3-[3-(4-aminophenylamino)propyl]-1-methyl-3H-imidazol-1-ium chloride;1-[3-(2,5-diaminophenoxy)propyl]-3-methyl-3H-imidazol-1-ium chloride;3-[3-(4-amino-3-methylphenylamino)propyl]-1-methyl-3H-imidazol-1-iumchloride;3-[3-(4-amino-2-methylphenylamino)propyl-1-methyl-3H-imidazol-1-iumchloride;1-[2-(4-amino-2-methoxyphenylamino)ethyl]-3-methyl-3H-imidazol-1-iumchloride;3-[3-(4-amino-2-fluorophenylamino)propyl]—methyl-3H-imidazol-1-iumchloride;3-[3-(4-amino-2-cyanophenylamino)propyl]-1-methyl-3H-imidazol-1-iumchloride and the addition salts thereof.
 16. The composition accordingto claim 14, wherein the monobenzenic paraphenylenediamines are1,3,-bis[3-(2,5,-diaminophenoxy)propyl]-3H-imidazol-1-ium monochloridetetrahydrochloride monohydrate.
 17. The composition according to claim13, wherein the dibenzenic para-phenylenediamines and dibenzenicpara-aminophenols are chosen from:1,3-bis-1{3{3′[(4″-amino-3″-methylaniline)-N-propyl]}-3H-imidazol-1-ium}propanedichloride;1,3-bis-1{3{3′[(4″-amino-2″-methylaniline)-N-propyl]}-3H-imidazol-1-ium}propanedichloride; 1,3-bis-1{3{3′[(4″-aminoaniline)-N-propyl]}-3H-imidazol-1-ium}propane dichloride;1,3-bis-1{3{3′[(4″-aminoaniline)-N-propylj}-3H-imidazol-1-ium}-2-propanoldichloride;N₁,N₃-bis-[3-N-(4′-aminoaniline)propyl]-1,1,3,3-tetramethyl-1,3-diammoniumpropanedibromide;1,4-bis-1{3[3-(2,5-diaminophenoxy)propyl]-3H-imidazol-1-ium)butanedichloride; 1,3-bis[3-(2,5-diaminophenoxy)propyl]-3H-imidazol-1-iummonochloride;N₁,N₄-bis-[3-N-methyl-N-(4′-aminoaniline)ethyl]-1,1,4,4-tetramethyl-1,3-diammoniumpropanedibromide;1,4-bis-1-[3-(5-amino-2-hydroxybenzyl)-3H-imidazol-1-ium]butanedichloride;1,3-bis-{[2-(4-aminoaniline)propyl]-1,1,3,3-tetramethyldiammoniumpropanedibromide;1,3-bis-{[4-(4-aminoaniline)pentyl]-1,1,3,3-tetramethyldiammoniumpropanedichloride;[4-(4-aminophenylamino)pentyl]-(5-amino-2-hydroxybenzyl)diethylammoniummonochloride;[2-(4-aminophenylamino)propyl]-(5-amino-2-hydroxybenzyl)dimethylammoniummonochloride;1,3-bis-1-{3-[3-(2,5-diaminophenoxy)propyl]-3H-imidazol-1-ium}propanedichloride;1,3-bis-1{3′(3′[(4″-aminoaniline)-N-propyl]}-3H-imidazol-1-ium}propanedichloride;1,3-bis-1{4{4′(4-[3-(4″-aminophenylamino)propyl]}-1,3-dimethyl-3H-imidazol-1-ium}propanedichloride;1,3-bis-1{4{4′(4-[3-(4″-amino-2″-methylaniline)propyl]}-1,3-dimethyl-3H-imidazol-1-ium}propanedichloride;4-[2-(2,5-diaminophenoxy)ethyl]-3-[3-(2,5-diaminophenoxy)propyl]-1-methyl-3-imidazol-1-iummonochloride;4-[2-(2,5-diaminophenoxy)ethyl]-1-[3-(2,5-diaminophenoxy)propyl]-3-methyl-3-imidazol-1-iummonochloride; and the addition salts thereof.
 18. The compositionaccording to claim 17, wherein the dibenzenic para-phenylenediamines anddibenzenic para-aminophenols are chosen from:1,3-bis-1{3{3′[(4″-aminoaniline)-N-propyl]}-3H-imidazol-1-ium}propanedichloride; 1,3-bis[3-(2,5-diaminophenoxy)propyl]-3H-imidazol-1-iummonochloride;N₁,N₄-bis-[3-N-methyl-N-(4′-aminoaniline)ethyl]-1,1,4,4-tetramethyl-1,3-diammoniumpropanedibromide;1,4-bis-1-[3-(5-amino-2-hydroxybenzyl)-3H-imidazol-1-ium]butanedichloride;1,3-bis-1{3{3′[(4″-aminoaniline)-N-propyl]}-3H-imidazol-1-ium}propanedichloride; and the addition salts thereof.
 19. The compositionaccording to claim 13, wherein the monobenzenic ortho-phenylenediaminesare chosen from: {2-[2-aminophenylamino]ethyl}trimethylammoniummonochloride; [2-(2-amino-5-chlorophenylamino)ethyl]trimethylammoniummonochloride; [2-(2-amino-6-chlorophenylamino)ethyl]trimethylammoniummonochloride; [2-(2-amino-4-chlorophenylamino)ethyl]trimethylammoniummonochloride;{2-[2-amino-4-chloro-5-(2-hydroxyethoxy)phenylamino]ethyl}trimethylammoniummonochloride; [2-(2-amino-5-methoxyphenylamino)ethyl]tri methylammoniummonochloride;[2-(2-aminophenylamino)ethyl]-(2-hydroxyethyl)dimethylammoniummonobromide; 4-[2-(2-aminophenylamino)ethyl]-4-methylmorpholin-4-iummonochloride; 1-[2-(2-aminophenylamino)ethyl]-1-ethylpiperidiniummonochloride;1-[2-(2-aminophenylamino)ethyl]-1,4-dimethylpiperazin-1-iummonochloride;4-[2-(1-methylpiperidinium)ethoxy]-N-2-[2-(1-methylpiperidinium)ethyl]benzene-1,2-diaminedichloride;1-[2-(2-amino-5-methylsulphanylphenylamino)ethyl]-1-methylpiperidiniummonochloride; 1-[2-(2-aminophenylamino)ethyl]-1-methylpyrrolidiniummonochloride; [3-(2-aminophenylamino)propyl]diethylmethylammoniummonochloride;N,N′-bis-[2-(1-methylpiperidinium)ethyl]benzene-1,2-diamine dichloride;[2-(2-amino-4-methylphenylamino)ethyl]trimethyl [lacuna] monochloride;3-[3-(2-aminophenylamino)propyl]-1-methyl-3H-imidazol-1-iummonochloride; 3-[2-(2-aminophenylamino)ethyl]-1-methyl-3H-imidazol-1-iummonochloride;4-[2-(1-methyl-3H-imidazol-1-ium)ethoxy]-N-2-[2-(1-methyl-3H-imidazol-1-ium)ethyl]benzene-1,2-diaminedichloride;3-[2-(2-amino-4-methylphenylamino)ethyl]-1-ethyl-3H-imidazol-1-iummonochloride;3-[3-(2-aminophenylamino)propyl]-1-(3-trimethylammonium-2-hydroxypropyl)-3H-imidazol-1-iumdichloride;3-[3-(2-aminophenylamino)propyl]-1-(2-hydroxyethyl)-3H-imidazol-1-iummonobromide;3-{[2-(2-aminophenylamino)ethylcarbamoyl]methyl}-1-methyl-3H-imidazol-1-iummonochloride; 1-[2-(2-amino-4-chlorophenylamino)ethyl]pyridiniummonochloride;3-[2-(2-amino-5-methoxyphenylamino)ethyl]-1-methyl-3H-imidazol-1-iummonochloride;3-[2-(2-amino-5-methylsulphanylphenylamino)ethyl]-1-methyl-3H-imidazol-1-iummonochloride; and the addition salts thereof.
 20. The compositionaccording to claim 19, wherein the monobenzenic ortho-phenylenediaminesare chosen from: {2-[2-aminophenylamino]ethyl}trimethylammoniumchloride; 3-[3-(2-aminophenylamino)propyl]-1-methyl-3H-imidazol-1-iumchloride; and the addition salts thereof.
 21. The composition accordingto claim 13, wherein the dibenzenic ortho-phenylenediamines are chosenfrom:1,3-bis-{3-{3-[(2-aminoaniline)-N-propyl]}-3H-imidazol-1-ium}propanedibromide;N₁,N₃-bis-[3-N-(2-aminoaniline)propyl]-1,1,3,3-tetramethyl-1,3-diammoniumpropanedibromide;1,4-bis-{3-{2-[(2-aminoaniline)-N-ethyl]}-3H-imidazol-1-ium}butanedichloride; 1-[2(2-aminoaniline)ethyl]-3-[3-(2-aminoaniline)propyl]-3H-imidazol-1-iummonochloride; and the addition salts thereof.
 22. The compositionaccording to claim 21, wherein the dibenzenic ortho-phenylenediaminesare chosen from:1,3-bis-1-{3-{3-[(2-aminoaniline)-N-propyl]}-3H-imidazol-1-ium}propanedibromide;N₁,N₃-bis-[3-N-(2-aminoaniline)propyl]-1,1,3,3-tetramethyl-1,3-diammoniumpropanedibromide; and the addition salts thereof.
 23. The composition accordingto claim 13, wherein the heterocyclic oxidation bases of the pyrazoletype are chosen from:[3-(4-amino-2,5-dimethyl-2H-pyrazol-3-ylamino)propyl]trimethylammoniumchloride;[3-(4-amino-2,5-dimethyl-2H-pyrazol-3-ylamino)propyl]-(2-hydroxyethyl)dimethylammoniumchloride;3-[3-(4-amino-2,5-dimethyl-2H-pyrazol-3-ylamino)propyl]-1-(2-hydroxyethyl)-3H-imidazol-1-iumchloride;3-[(4-amino-2H-pyrazol-3-ylcarbamoyl)methyl]-1-methyl-3H-imidazol-1-iumchloride;3-[2-(4,5-diamino-3-methylpyrazol-1-yl)ethyl]-1-methyl-3H-imidazol-1-iumchloride;3-[2-(4,5-diaminopyrazol-1-yl)ethyl]-1-methyl-3H-imidazol-1-iumchloride; [2-(4,5-diamino-3-methylpyrazol-1-yl)ethyl]trimethylammoniumchloride; [2-(4,5-diaminopyrazol-1-yl)ethyl]trimethylammonium chloride;[2-(4-amino-5-hydroxypyrazol-1-yl)ethyl]trimethylammonium chloride;[2-(4-amino-5-hydroxy-3-methylpyrazol-1-yl)ethyl]trimethylammoniumchloride;3-[2-(4-amino-5-hydroxy-3-methylpyrazol-1-yl)ethyl]-1-methyl-3H-imidazol-1-iumchloride;3-[2-(4-amino-5-hydroxypyrazol-1-yl)ethyl]-1-methyl-3H-imidazol-1-iumchloride;3-[2-(4,5-diamino-1-methyl-1H-pyrazol-3-yl)ethyl]-1-methyl-3H-imidazol-1-iumchloride; and the addition salts thereof, and the possible tautomericforms thereof.
 24. The composition according to claim 23, wherein theheterocyclic oxidation bases of the pyrazole type are chosen from:[3-(4-amino-2,5-dimethyl-2H-pyrazol-3-ylamino)propyl]trimethylammoniumchloride;[3-(4-amino-2,5-dimethyl-2H-pyrazol-3-ylamino)propyl]-(2-hydroxyethyl)dimethylammoniumchloride;3-[3-(4-amino-2,5-dimethyl-2H-pyrazol-3-ylamino)propyl]-1-(2-hydroxyethyl)-3H-imidazol-1-iumchloride;3-[(4-amino-2H-pyrazol-3-ylcarbamoyl)methyl]-1-methyl-3H-imidazol-1-iumchloride;3-[2-(4,5-diamino-3-methylpyrazol-1-yl)ethyl]-1-methyl-3H-imidazol-1-iumchloride;3-[2-(4,5-diamino-1-methyl-1H-pyrazol-3-yl)ethyl]-1-methyl-3H-imidazol-1-iumchloride, and the addition salts thereof, and the possible tautomericforms thereof.
 25. The composition according to claim 13, wherein theheterocyclic oxidation bases of the pyrazolo[1,5-a]pyrimidine type arechosen from:1-[3-(3-amino-5,6-dimethylpyrazolo[1,5-a]pyrimidin-7-ylamino)propyl]-3-methyl-3H-imidazol-1-iummonobromide, 3-[3-(3-amino-5-methylpyrazolo[1,5-a]pyri midin-7-ylamino)propyl]-1-(2-hydroxyethyl)-3H-imidazol-1-ium chloride,3-[(3-aminopyrazolo[1,5-a]pyrimidin-7-ylcarbamoyl)methyl]-1-methyl-3H-imidazol-1-iumchloride,3-(3-amino-7-hydroxy-5-methylpyrazolo[1,5-a]pyrimidin-6-ylmethyl)-1-methylpyridiniummethyl sulphate,3-(3-amino-7-hydroxy-5-methylpyrazolo[1,5-a]pyrimidin-6-ylmethyl)-1-(2-hydroxyethyl)pyridiniumchloride,2-[(3-aminopyrazolo[1,5-a]pyrimidin-7-ylamino)methyl]-1,3-dimethyl-3H-imidazol-1-iummethyl sulphate,3-[(3-aminopyrazolo[1,5-a]pyrimidin-7-ylamino)methyl]-1-methylpyridiniummethyl sulphate,3-[(3-aminopyrazolo[1,5-a]pyrimidin-7-ylamino)methyl]-1-methylpyridiniummethyl sulphate, 2-(3,7-diamino-5-methylpyrazolo[1,5-a]pyri midin-6-ylmethyl]-1,3-dimethyl-3H-imidazol-1-ium methyl sulphate,2-(3-amino-7-hydroxy-5-methylpyrazolo[1,5-a]pyrimidin-6-ylmethyl)-1,3-dimethyl-3H-imidazol-1-iummethyl sulphate,2-(3,7-diaminopyrazolo[1,5-a]pyrimidin-2-yl)-1-methylpyridinium methylsulphate,[3-(3-amino-5-methylpyrazolo[1,5-a]pyrimidin-7-ylamino)propyl]trimethylammoniumchloride,[3-(3-amino-5-methylpyrazolo[1,5-a]pyrimidin-7-ylamino)propyl]trimethylammoniummethyl sulphate,1-[3-(3-amino-5-methylpyrazolo[1,5-a]pyrimidin-7-ylamino)propyl]-1-methylpiperidiniumchloride,1-[3-(3-amino-5-methylpyrazolo[1,5-a]pyrimidin-7-ylamino)propyl]-1-methylpiperidiniummethyl sulphate,4-[3-(3-amino-5-methylpyrazolo[1,5-a]pyrimidin-7-ylamino)propyl]-4-methylmorpholin-4-iumchloride,4-[3-(3-amino-5-methylpyrazolo[1,5-a]pyrimidin-7-ylamino)propyl]-4-methylmorpholin-4-iummethyl sulphate, and the addition salts thereof.
 26. The compositionaccording to claim 25, wherein the heterocyclic oxidation bases of thepyrazolo[1,5-a]pyrimidine type are chosen from:1-[3-(3-amino-5,6-dimethylpyrazolo[15-a]pyrimidin-7-ylamino)propyl]-3-methyl-3H-imidazol-1-iummonobromide,3-[3-(3-amino-5-methylpyrazolo[1,5-a]pyrimidin-7-ylamino)propyl]-1-(2-hydroxyethyl)-3H-imidazol-1-iumchloride, 3-(3-amino-7-hydroxy-5-methylpyrazolo[1,5-a]pyrimidin-6-ylmethyl)-1-methylpyridinium methyl sulphate,3-(3-amino-7-hydroxy-5-methylpyrazolo[1,5-a]pyrimidin-6-ylmethyl)-1-(2-hydroxyethyl)pyridiniumchloride,3-(3-amino-7-hydroxy-5-methylpyrazolo[1,5-a]pyrimidin-6-ylmethyl)-1-methylpyridiniumchloride,4-[3-(3-amino-5-methylpyrazolo[1,5-a]pyrimidin-7-ylamino)propyl]-4-methylmorpholin-4-iumchloride,4-[3-(3-amino-5-methylpyrazolo[1,5-a]pyrimidin-7-ylamino)propyl]-4-methylmorpholin-4-iummethyl sulphate, and the addition salts thereof.
 27. The compositionaccording to claim 1, wherein the at least one coupler is chosen frommeta-phenylenediamines, meta-aminophenols, meta-diphenols, naphthaleniccouplers and heterocyclic couplers, and the addition salts thereof. 28.The composition according to claim 27, wherein the at least one coupleris present in an amount ranging from 0.001% to 10% by weight, relativeto the total weight of the dye composition.
 29. The compositionaccording to claim 1, further comprising at least one additionalnon-cationic oxidation base chosen from para-phenylenediamines,bis(phenyl)alkylenediamines, para-aminophenols, ortho-aminophenols andheterocyclic bases, other than the at least one first oxidation base,and the addition salts thereof.
 30. The composition according to claim1, wherein the amount of each of said at least one first oxidation baseincluded in the composition ranges from 0.001% to 10% by weight,relative to the total weight of the dye composition.
 31. The compositionaccording to claim 1, further comprising at least one oxidizing agent.32. The composition according to claim 31, wherein the at least oneoxidizing agent is chosen from hydrogen peroxide, urea peroxide, alkalimetal bromates, persalts, peracids and oxidase enzymes.
 33. Thecomposition according to claim 1, further comprising at least one directdye chosen from nitrobenzene direct dyes, azo direct dyes, and methinedirect dyes.
 34. The composition according to claim 33, wherein the atleast one direct dye is nonionic, anionic, or cationic in nature.
 35. Aprocess for oxidation dyeing of keratin fibres, comprising applying tothe keratin fibres at least one dye composition comprising, in a mediumsuitable for dyeing, at least one first oxidation base chosen from4,5-diaminopyrazole derivatives of formula (I) and the addition saltsthereof,

wherein R¹ is chosen from C₁-C₆ alkyl radicals substituted with at leastone radical chosen from OR² radicals wherein R² is chosen from C₁-C₆alkyl radicals; at least one second cationic oxidation base chosen frommonobenzenic, dibenzenic and heterocyclic oxidation bases, and theaddition salts thereof, wherein said at least one second cationicoxidation base comprises at least one cationic group Z chosen fromaliphatic chains optionally bearing at least one ring chosen fromsaturated and unsaturated rings; wherein said at least one cationicgroup Z is linked directly to at least one benzenic ring or to at leastone heterocycle of said at least one second cationic oxidation base orlinked to at least one amine functional group borne by said at least onebenzenic ring or said at least one heterocycle; and at least onecoupler; and at least one oxidizing agent.
 36. The process according toclaim 35, wherein the at least one oxidizing agent is chosen fromhydrogen peroxide, urea peroxide, alkali metal bromates, persalts,peracids and oxidase enzymes.
 37. The process according to claim 35,comprising mixing, at the time of use, the at least one oxidizing agentwith the at least one dye composition.
 38. A process for oxidationdyeing of keratin fibres, comprising applying to the keratin fibres atleast one oxidizing composition comprising, in a medium suitable fordyeing, at least one oxidizing agent, simultaneously or sequentially toat least one dye composition comprising, in a medium suitable fordyeing, at least one first oxidation base chosen from4,5-diaminopyrazole derivatives of formula (I) and the addition saltsthereof,

wherein R¹ is chosen from C₁-C₆ alkyl radicals substituted with at leastone radical chosen from OR² radicals wherein R² is chosen from C₁-C₆alkyl radicals; at least one second cationic oxidation base chosen frommonobenzenic, dibenzenic and heterocyclic oxidation bases, and theaddition salts thereof, wherein said at least one second cationicoxidation base comprises at least one cationic group Z chosen fromaliphatic chains optionally bearing at least one ring chosen fromsaturated and unsaturated rings; wherein said at least one cationicgroup Z is linked directly to at least one benzenic ring or to at leastone heterocycle of said at least one second cationic oxidation base orlinked to at least one amine functional group borne by said at least onebenzenic ring or said at least one heterocycle; and at least onecoupler.
 39. A multi-compartment kit or device comprising a firstcompartment comprising at least one dyeing composition comprising, in amedium suitable for dyeing, at least one first oxidation base chosenfrom 4,5-diaminopyrazole derivatives of formula (I) and the additionsalts thereof,

wherein R¹ is chosen from C₁-C₆ alkyl radicals substituted with at leastone radical chosen from OR² radicals wherein R² is chosen from C₁-C₆alkyl radicals; at least one second cationic oxidation base chosen frommonobenzenic, dibenzenic and heterocyclic oxidation bases, and theaddition salts thereof, wherein said at least one second cationicoxidation base comprises at least one cationic group Z chosen fromaliphatic chains optionally bearing at least one ring chosen fromsaturated and unsaturated rings; wherein said at least one cationicgroup Z is linked directly to at least one benzenic ring or to at leastone heterocycle of said at least one second cationic oxidation base orlinked to at least one amine functional group borne by said at least onebenzenic ring or said at least one heterocycle; and at least onecoupler; and a second compartment comprising at least one oxidizingcomposition.
 40. A process for dyeing keratin fibres, comprisingapplying to keratin fibres a dye composition comprising, in a mediumsuitable for dyeing, at least one first oxidation base chosen from4,5-diaminopyrazole derivatives of formula (I) and the addition saltsthereof,

wherein R¹ is chosen from C₁-C₆ alkyl radicals substituted with at leastone radical chosen from OR² radicals wherein R² is chosen from C₁-C₆alkyl radicals; at least one second cationic oxidation base chosen frommonobenzenic, dibenzenic and heterocyclic oxidation bases, and theaddition salts thereof, wherein said at least one second cationicoxidation base comprises at least one cationic group Z chosen fromaliphatic chains optionally bearing at least one ring chosen fromsaturated and unsaturated rings; wherein said at least one cationicgroup Z is linked directly to at least one benzenic ring or to at leastone heterocycle of said at least one second cationic oxidation base orlinked to at least one amine functional group borne by said at least onebenzenic ring or said at least one heterocycle; and at least onecoupler.
 41. A process for manufacturing a dye composition comprisingincluding in the dye composition at least one first oxidation basechosen from 4,5-diaminopyrazole derivatives of formula (I) and theaddition salts thereof,

wherein R¹ is chosen from C₁-C₆ alkyl radicals substituted with at leastone radical chosen from OR² radicals wherein R² is chosen from C₁-C₆alkyl radicals; at least one second cationic oxidation base chosen frommonobenzenic, dibenzenic and heterocyclic oxidation bases, and theaddition salts thereof, wherein said at least one second cationicoxidation base comprises at least one cationic group Z chosen fromaliphatic chains optionally bearing at least one ring chosen fromsaturated and unsaturated rings; wherein said at least one cationicgroup Z is linked directly to at least one benzenic ring or to at leastone heterocycle of said at least one second cationic oxidation base orlinked to at least one amine functional group borne by said at least onebenzenic ring or said at least one heterocycle; and at least onecoupler.